116 related articles for article (PubMed ID: 2434782)
1. Role of vasopressin in experimental congestive cardiac failure.
Johnston CI; Arnolda L; Abrahams J; McGrath B
J Cardiovasc Pharmacol; 1986; 8 Suppl 7():S96-100. PubMed ID: 2434782
[TBL] [Abstract][Full Text] [Related]
2. Vasoconstrictor role for vasopressin in experimental heart failure in the rabbit.
Arnolda L; McGrath BP; Cocks M; Johnston CI
J Clin Invest; 1986 Sep; 78(3):674-9. PubMed ID: 3528220
[TBL] [Abstract][Full Text] [Related]
3. Vasopressin and angiotensin II contribute equally to the increased afterload in rabbits with heart failure.
Arnolda L; McGrath BP; Johnston CI
Cardiovasc Res; 1991 Jan; 25(1):68-72. PubMed ID: 2054832
[TBL] [Abstract][Full Text] [Related]
4. Adriamycin cardiomyopathy in the rabbit: an animal model of low output cardiac failure with activation of vasoconstrictor mechanisms.
Arnolda L; McGrath B; Cocks M; Sumithran E; Johnston C
Cardiovasc Res; 1985 Jun; 19(6):378-82. PubMed ID: 4016815
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular responses to graded treadmill exercise during the development of doxorubicin induced heart failure in rabbits.
Langton D; Jover B; McGrath BP; Ludbrook J
Cardiovasc Res; 1990 Dec; 24(12):959-68. PubMed ID: 2097062
[TBL] [Abstract][Full Text] [Related]
6. Contribution of vasopressin to vasoconstriction in patients with congestive heart failure: comparison with the renin-angiotensin system and the sympathetic nervous system.
Creager MA; Faxon DP; Cutler SS; Kohlmann O; Ryan TJ; Gavras H
J Am Coll Cardiol; 1986 Apr; 7(4):758-65. PubMed ID: 3514728
[TBL] [Abstract][Full Text] [Related]
7. Acute effects of digoxin on total systemic vascular resistance in congestive heart failure due to dilated cardiomyopathy: a hemodynamic-hormonal study.
Ribner HS; Plucinski DA; Hsieh AM; Bresnahan D; Molteni A; Askenazi J; Lesch M
Am J Cardiol; 1985 Nov; 56(13):896-904. PubMed ID: 3904388
[TBL] [Abstract][Full Text] [Related]
8. Vasopressin and renin in high output heart failure of rats: hemodynamic effects of elevated plasma hormone levels.
Riegger GA; Liebau G; Bauer E; Kochsiek K
J Cardiovasc Pharmacol; 1985; 7(1):1-5. PubMed ID: 2580126
[TBL] [Abstract][Full Text] [Related]
9. Hypotension during vasopressin receptor blockade: role of V2 receptors and sympathetic nervous system.
Brooks VL; Hatton DC
Am J Physiol; 1991 Jun; 260(6 Pt 2):H1878-87. PubMed ID: 1829332
[TBL] [Abstract][Full Text] [Related]
10. Neurohumoral vasoconstrictor systems in heart failure.
Riegger AJ
Eur Heart J; 1985 Jun; 6(6):479-89. PubMed ID: 2864248
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular and hormonal effects of calcitonin gene-related peptide in congestive heart failure.
Anand IS; Gurden J; Wander GS; O'Gara P; Harding SE; Ferrari R; Cornacchiari A; Panzali A; Wahi PL; Poole-Wilson PA
J Am Coll Cardiol; 1991 Jan; 17(1):208-17. PubMed ID: 1987228
[TBL] [Abstract][Full Text] [Related]
12. Hemodynamic effects of vasopressin compared with angiotensin II in conscious rats.
Osborn JW; Skelton MM; Cowley AW
Am J Physiol; 1987 Mar; 252(3 Pt 2):H628-37. PubMed ID: 3826404
[TBL] [Abstract][Full Text] [Related]
13. Hemodynamic effects of infused arginine vasopressin in congestive heart failure.
Goldsmith SR; Francis GS; Cowley AW; Goldenberg IF; Cohn JN
J Am Coll Cardiol; 1986 Oct; 8(4):779-83. PubMed ID: 3760354
[TBL] [Abstract][Full Text] [Related]
14. Role of the renin-angiotensin system in the development of congestive heart failure in the dog as assessed by chronic converting-enzyme blockade.
Riegger GA; Liebau G; Holzschuh M; Witkowski D; Steilner H; Kochsiek K
Am J Cardiol; 1984 Feb; 53(4):614-8. PubMed ID: 6320625
[TBL] [Abstract][Full Text] [Related]
15. Systemic and regional effects of vasopressin and angiotensin in acute left ventricular failure.
Arnolda L; McGrath BP; Johnston CI
Am J Physiol; 1991 Feb; 260(2 Pt 2):H499-506. PubMed ID: 1825456
[TBL] [Abstract][Full Text] [Related]
16. Clinical studies with a vascular vasopressin antagonist.
Waeber B; Nussberger J; Hofbauer KG; Nicod P; Brunner HR
J Cardiovasc Pharmacol; 1986; 8 Suppl 7():S111-6. PubMed ID: 2434764
[TBL] [Abstract][Full Text] [Related]
17. Suppressing sympathetic activation in congestive heart failure. A new therapeutic strategy.
Manolis AJ; Olympios C; Sifaki M; Handanis S; Bresnahan M; Gavras I; Gavras H
Hypertension; 1995 Nov; 26(5):719-24. PubMed ID: 7591009
[TBL] [Abstract][Full Text] [Related]
18. Responses of vasoactive hormones in congestive cardiac failure.
Johnston CI; Arnolda LF; Tsunoda K; Phillips PA; Hodsman GP
Can J Physiol Pharmacol; 1987 Aug; 65(8):1706-11. PubMed ID: 2961425
[TBL] [Abstract][Full Text] [Related]
19. Baroreceptor-mediated release of vasopressin in patients with chronic congestive heart failure and defective sympathetic responsiveness.
Manthey J; Dietz R; Opherk D; Osterziel KJ; Leinberger H; Kübler W
Am J Cardiol; 1992 Jul; 70(2):224-8. PubMed ID: 1626511
[TBL] [Abstract][Full Text] [Related]
20. Effects of vasopressin on heart rate in conscious rabbits.
Elliott JM; West MJ; Chalmers J
J Cardiovasc Pharmacol; 1985; 7(1):6-11. PubMed ID: 2580152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
